COVID-19 trials registries data warehouse

 Return to trial list

Trial - IRCT20201024049134N3


Column Value
Trial registration number IRCT20201024049134N3
Full text link
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

First author
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Reza Ghadimi

Contact
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

rezaghadimi@yahoo.com

Registration date
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2021-06-21

Recruitment status
Last imported at : Dec. 22, 2021, 5:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Completed

Study design
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

RCT

Allocation
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Randomized

Design
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Parallel

Masking
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Blind label

Center
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

single-center

Study aim
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Treatment

Inclusion criteria
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Men and women of at least 18 years of age capable of providing informed consent. Confirmation of COVID-19 with RT-PCR in the last 24 hours Patients with outpatient treatment status (do not have any of the following): PaO2/FiO2 < 300, SpO2 < 93%, Respiratory rate > 30, Progressive lung involvements in CT scan The patient must meet at least one of the following high-risk criteria: 70 years of age or older, obesity (BMI ≥ 30 kg/m2), diabetes, uncontrolled blood pressure (systolic blood pressure > 150 mm Hg), known case of respiratory disease (Including asthma or COPD), known case of heart failure, known case of coronary artery disease, fever > 38.4°C in the last 48 hours, shortness of breath at the time of enrollment, Bicytopenia, Pancytopenia or a combination of neutrophilia and lymphopenia

Exclusion criteria
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

The patient is currently hospitalized or needs immediate care and hospitalization. Showing any symptoms of shock or hemodynamic instability. History of inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption. History of progressive neuromuscular disease. Estimated glomerular filtration rate (eGFR) < 30 ml/min in 1.73 m2 using MDRD equation. History of cirrhosis, chronic active hepatitis or severe liver disease. Pregnant, breastfeeding, or women Intending to get pregnant during the study period or 6 months after the last dose of study agent. History of colchicine use for other conditions, including Familial Mediterranean Fever or gout. History of allergic reaction or severe sensitivity to colchicine. Cancer patients undergoing active chemotherapy.

Number of arms
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2

Funding
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Babol University of Medical Sciences

Inclusion age min
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

18

Inclusion age max
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

100

Countries
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Iran

Type of patients
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Mild/moderate disease at enrollment

Severity scale
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

2: Mild/moderate disease at enrollment

Total sample size
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

500

primary outcome
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Require hospitalization Severely ill Death

Notes
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Phase
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

Phase 2/Phase 3

Arms
Last imported at : June 22, 2021, 1:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)

[{"arm_notes": "", "treatment_id": 310, "treatment_name": "Colchicine", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]